small molecule

LUXIQ

BETAMETHASONE VALERATE

Loss of exclusivityloss of exclusivity
CompanyPHARMOBEDIENT CONSULTING LLC

Drug detail

Brand nameLUXIQ
Active ingredientBETAMETHASONE VALERATE
Strength0.12% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalFebruary 1999
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

LUXIQ patent cliff — loss of exclusivity — | CliffBio